XML 45 R33.htm IDEA: XBRL DOCUMENT v3.24.3
Segment Information (Tables)
9 Months Ended
Sep. 30, 2024
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information, by Segment
Information regarding net sales and operating profit (loss) for the three months ended September 30, 2024 and 2023 are as follows (in millions):

Life
Science
Clinical
Diagnostics
Other
Operations
Net sales2024$260.9 $388.8 $— 
 2023$263.5 $368.1 $0.5 
Operating profit (loss)2024$(9.8)$74.2 $0.1 
 2023$13.0 $78.0 $(0.1)

Information regarding Net sales and operating profit (loss) for the nine months ended September 30, 2024 and 2023 are as follows (in millions):

Life
Science
Clinical
Diagnostics
Other
Operations
Net sales2024$753.1 $1,145.4 $0.5 
 2023$887.3 $1,100.3 $2.5 
Operating profit (loss)2024$1.1 $209.9 $(0.3)
 2023$76.7 $166.1 $(0.3)
Reconciliation of Operating Profit (Loss) from Segments to Consolidated
The following reconciles total operating profit to consolidated income (loss) before income taxes (in millions):

Three Months EndedNine Months Ended
September 30,September 30,
 2024202320242023
Operating profit$64.5 $90.9 $210.7 $242.5 
Interest expense(12.2)(12.3)(36.7)(37.2)
Foreign currency exchange (losses) gains, net
(1.6)1.7 2.0 5.3 
Gains (losses) from change in fair market value of equity securities and loan receivable
792.8 36.4 (1,680.3)(1,576.5)
Other income, net18.1 20.4 70.7 87.4 
Consolidated income (loss) before income taxes
$861.6 $137.1 $(1,433.6)$(1,278.5)